Thursday January 24, 2019 Temperature-Stable Experimental Tuberculosis Vaccine Enters Clinical Testing An NIAID-supported Phase 1 clinical trial testing a freeze-dried, temperature stable formulation of an experimental TB vaccine regimen is ongoing at the Saint Louis University School of Medicine Center for Vaccine Development. The experimental vaccine, called ID93, was developed by scientists at the Infectious Disease Research Institute in Seattle. Investigators are examining if a powder formulation combining the vaccine and the adjuvant GLA-SE in a single vial, reconstituted with sterile water, is as effective at inducing an immune response in participants as the previously-tested two-vial combination of powdered ID93 and liquid GLA-SE. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107